{
    "clinical_study": {
        "@rank": "21572", 
        "acronym": "UFREEZE-01", 
        "arm_group": {
            "arm_group_label": "symptomatic UF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The goal of this study is to evaluate the safety & efficacy of cryoablation using IceCure\n      medical's IceSense3\u2122 device for the treatment of symptomatic uterine fibroids in a\n      percutaneous lap-assisted approach."
        }, 
        "brief_title": "Laparoscopic Cryoablation of Uterine Fibroids", 
        "condition": "Symptomatic Uterine Fibroids", 
        "condition_browse": {
            "mesh_term": [
                "Leiomyoma", 
                "Myofibroma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pre-menopausal woman between the ages of 30 and 50 (inclusive)\n\n          2. Patient had completed her family planning and does not desire future   childbearing.\n\n          3. Patient is suffering from menorrhagia as a result of symptomatic uterine fibroids.\n\n          4. Patient's uterus size is smaller than 18 gestational weeks.\n\n          5. Patient wishes to preserve her uterus and avoid hysterectomy.\n\n          6. Patient has 1-3 treatable uterine fibroids in size of up to 10cm measured by US/MRI.\n\n          7. Overall treated fibroid volume is \u2264 3,138cm3 (width x length x height x 0.523)\n\n          8. Patient has clinical menorrhagia as indicated by menstrual blood loss of \u2265160 ml\n             during one baseline cycle prior to treatment.\n\n          9. Patient is able to visit the clinic as needed during the 1 year follow-up period\n             following the treatment.\n\n         10. The patient has been informed of the study and agrees to its provisions, and has\n             signed an IRB approved written informed consent, including data privacy\n             authorization.\n\n        Exclusion Criteria:\n\n          1. Patient had not finished her family planning\n\n          2. Patient was already treated for uterine fibroids in the past (UAE, myomectomy,\n             HIFU,\u2026) or undergone endometrial ablation.\n\n          3. Patient had been treated with GnRH over the last 3 months.\n\n          4. Patient has known symptomatic endometriosis that cannot be completely removed during\n             laparoscopic procedure.\n\n          5. Patient has known or suspected adenomyosis\n\n          6. Patient had any active abdominal/pelvic inflammatory disease.\n\n          7. Patient has known or suspected gynecologic malignancy.\n\n          8. Patient with submucosal fibroids type \"zero\"\n\n          9. Patient with undiagnosed vaginal bleeding\n\n         10. Patient with blood clotting disorders\n\n         11. Patients carrying contagious diseases such as Tuberculosis Hepatitis or AIDS.\n\n         12. Patient participating in other trials using drugs or devices.\n\n         13. Patient is unable to commit all study requirements including follow-up visits and\n             questionnaires.\n\n         14. Patient has any contraindication for laparoscopic surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735812", 
            "org_study_id": "ICUFL-01"
        }, 
        "intervention": {
            "arm_group_label": "symptomatic UF", 
            "description": "The IceSense3\u2122 is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.", 
            "intervention_name": "IceSense3 system", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cryoablation", 
            "uterine fibroid", 
            "uterine myoma", 
            "who completed her family planning", 
            "but wishes to preserve her uterus"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": {
            "contact": {
                "last_name": "Moty Pansky, Prof."
            }, 
            "facility": {
                "address": {
                    "city": "Zrifin", 
                    "country": "Israel", 
                    "zip": "70300"
                }, 
                "name": "Assaf Harofe"
            }, 
            "investigator": {
                "last_name": "Moty Pansky, Prof", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3\u2122 System in a Percutaneous Laparoscopic-assisted Approach", 
        "other_outcome": [
            {
                "description": "Patient's and physician's overall treatment evaluation and satisfaction will be assessed using a self-report questionnaire at 6 and 12 months post treatment.", 
                "measure": "Patient's and physician's overall treatment evaluation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Patient blood loss will be also evaluated by Hemoglobin (Hb) level measurements at 6 and 12 months post treatment and will be compared to baseline.", 
                "measure": "Patient blood loss", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "Elisabeth@Icecure-medical.com", 
            "last_name": "Elisabeth Sadka, Mrs", 
            "phone": "972 4 623 0333", 
            "phone_ext": "223"
        }, 
        "overall_contact_backup": {
            "email": "tal@icecure-medical.com", 
            "last_name": "Tal Avziz, Mr.", 
            "phone": "972 4 623 0333", 
            "phone_ext": "127"
        }, 
        "overall_official": {
            "affiliation": "Assaf Harofe Hospital, Israel", 
            "last_name": "Moty Pansky, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate procedural efficacy by the improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 12 months post-treatment comparing to baseline score.", 
                "measure": "Improvement in patient's fibroid-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To evaluate procedural safety by monitoring incidence, subsequent interventions and procedure-related adverse events within 12 months of treatment", 
                "measure": "Incidence, subsequent interventions and procedure-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735812"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction in fibroid volume as measured by US/MRI imaging at 6 and 12 months follow-up post treatment comparing to baseline.", 
                "measure": "Reduction in fibroid volume", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Improvement in menstrual bleeding compared to baseline as measured in chemical analysis (Alkaline haematin technique) at 6 and 12 months post treatment.", 
                "measure": "Improvement in menstrual bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Improvement in patient's fibroid-related quality of life as assessed in scores of symptom severity subscale questionnaire (SSS-UFS-QOL) at 6 months post-treatment comparing to baseline score.", 
                "measure": "Improvement in patient's fibroid-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "IceCure Medical Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IceCure Medical Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}